Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 30, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/30/16 - 2016 Update of Biosimilar & Biosuperior Therapeutic Antibodies - Competitor Analysis: MarketResearchReports.Biz
MarketResearchReports.Biz has announced addition of new report Competitor Analysis: Biosimilar& Biosuperior Therapeutic Antibodies- 2016 Update to its database.Albany, NY 05/30/2016 This Competitive Intelligence report about Biosimilar& Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic...
5/30/16 - AB Science Will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21st Congress of the European Hematology Association
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, today announced that results from its phase 3 trial in severe systemic mastocytosis will be presented as an oral presentation at the 21 st Congress of the European Hematology Association. Professor Olivier Hermine,
5/30/16 - abpi- The future of research lies with today's young people
Release date- 27052016- The UK pharmaceutical industry is passionate about the life sciences and we are always keen to encourage an interest in research. We recognise that the future of success for our industry and, more importantly, the future healthcare for patients in the UK, lies in the next generation. Over more than 10 years we have built up
5/30/16 - Acasti Announces Grant of Stock Options
Acasti Pharma Inc., an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces the grant of 310,400 stock options under its Stock Option Plan to its employees, including 200,000 to the...
5/30/16 - Acquisitions deliver dose of healthy sales growth for Alliance Pharma [Qatar Tribune]
Alliance Pharma, the specialty pharmaceutical company, has chalked up annual UK sales growth of 20% as its spate of recent acquisitions pay off. This was in marked contrast just over a year ago when Alliance Pharma revealed a fall in sales and profits after what its chairman described as a challenging year. The 20% increase in UK sales to 2.9 m was
5/30/16 - Alibaba tells vendors to halt drug sales online, cites government rule change [Egypt Independent]
Chinese e-commerce firm Alibaba Group Holding Ltd has told vendors on its Tmall website to stop selling medicine, saying a local regulator has issued an "urgent" directive halting drug sales via third-party platforms. Alibaba, in a notice dated May 27 seen by Reuters, cited a circular from the Hebei province branch of the China Food and Drug Admini
5/30/16 - Aurobindo Pharma likely to deliver strong growth in Q4 [Khaleej Times (United Arab Emirates)]
Aurobindo Pharma, a leading pharmaceutical company in the country, will announce its financial results for the fourth quarter ended March 31, 2016 on May 30. IIFL estimates the companys net profit to be at Rs.549 crore, which constitutes a rise of 35.9% yoy and 2.6% qoq. Key quarterly results on May 30 include APL Apollo Tubes, Atul Auto, Aurobindo
5/30/16 - AZN's Falcon Hits Goal, FDA Approves MS Drug, CANF Awaits Data In June
WESTON- ZINBRYTA, jointly developed by Biogen Inc. and AbbVie, has been granted FDA approval for relapsing forms of multiple sclerosis. Shares of Atossa Genetics Inc. rose more than 11% on Friday, following a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration sta
5/30/16 - Bajaj Electricals net profit likely to drop yoy [India Infoline News Service]
Bajaj Electricals, a leading pharmaceutical company in the country, will announce its financial results for the fourth quarter ended March 31, 2016 on May 30. As per IIFL's forecast, the company is expected to register a net revenue of Rs.1, 426 crore, growing at 8.7% yoy and 24.4% on qoq basis. Operating profit margin of the company is likely to b
5/30/16 - Bharat Book Bureau: Market Performance of Chinese Listed Bio-pharmaceutical Companies in 2015
Biopharmaceutical industry of China developed behind the leading countries, however, it is growing dramatically fast during past decades. At present, biopharmaceutical industry is one of the leading industries in China. -To understand the development situation of bio-pharmaceutical industry in China;.
5/30/16 - Bharat Book Bureau: Market Performance of Chinese Listed Civil Aviation Companies in 2015
China has the fastest growing total volume of any country in the world. There were 21 listed biopharmaceutical companies in 2015, the industry turned in a total profit of 54.8 billion yuan in the first 11 months of 2015, up 76.2 per cent year on year, according to the Civil Aviation Administration of China. -To understand the development situation
5/30/16 - Boehringer expects UAE sales growth to reach double digits [Seven Days (United Arab Emirates)]
Boehringer Ingelheim, a German pharmaceutical company, expects to post double-digit sales growth in the UAE on the back of new product launches this year, according to a top official. Last year the company reported annual UAE sales growth of 34 per cent and 26 per cent across the wider Mena region. Consultants Euromonitor International believe the
5/30/16 - Can-Fite Reports First Quarter 2016 Financial Results %7E Provides Clinical Pipeline Update [Global Data Point]
In June 2016, Can-Fite plans to report data from a Phase II trial of CF101, conducted by its subsidiary OphthaliX, in the treatment of glaucoma and related syndromes of ocular hypertension.&# x0D;. On March 7, 2016, Can-Fite presented data at the American Academy of Dermatology's 74th Annual Meeting in Washington D.C. in a poster titled, "Treatment
5/30/16 - Crackdown on spurious drugs continues
Sources associated with manufacturing of medicines revealed that mostly such brands were belonged to aphrodisiac medicines which are smuggled from India and China. As per an estimation a big market of Rs 3.76 billion belonged to aphrodisiac drugs. Besides these aphrodisiac medicines a big number of nutrauceutical, herbal, cosmetics medicines, ayurv
5/30/16 - Efficacy and safety of the new macrolide antibiotic 'T-4288' confirmed in Phase II clinical trial in Japan
Release date- 27052016- Fujifilm Group company Toyama Chemical Co., Ltd. has announced the result of its Phase II clinical trial of' T-4288' on community-acquired pneumonia patients in Japan confirming its efficacy and safety. In the United States, Cempra submitted a New Drug Application for its approval with the U.S. Food and Drug Administration f
5/30/16 - FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC [Arab News (Saudi Arabia)]
-Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration has granted accelerated approval to Ocaliva for the treatment of primary biliary cholangitis, previously known
5/30/16 - FLIXABI, Biogen Infliximab Biosimilar Referencing Remicade, Approved In EU
FLIXABI was developed by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen. Earlier this year, Samsung Bioepis received approval for BENEPALI, a biosimilar referencing Enbrel. As part of the submission, Samsung Bioepis provided a robust preclinical and clinical data package from head-to-head Phase 1 and Phase 3 clinical trials
5/30/16 - FLIXABI, Biogen's Infliximab Biosimilar Referencing Remicade, Approved in the European Union
FLIXABI was developed by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen. Earlier this year, Samsung Bioepis received approval for BENEPALI , a biosimilar referencing Enbrel ii. The approval of FLIXABI marks a major step forward for both Samsung Bioepis and Biogen.
5/30/16 - Foundation Medicine Incorporated Sellers Covered 1.48% of Their Shorts [Daily Tribune (Bahrain)]
The stock of Foundation Medicine Incorporated registered a decrease of 1.48% in short interest. Foundation Medicine Inc has declined 14.98% since October 22, 2015 and is downtrending. Foundation Medicine, Inc. is a molecular information company.
5/30/16 - Genmab Achieves USD 30 Million Milestone in DARZALEX (daratumumab) Collaboration with Janssen
Genmab to receive USD 30 million milestone payment from Janssen Milestone triggered by first commercial sale of DARZALEX in Europe. Copenhagen, Denmark; May 30, 2016 Genmab A/S announced today it has achieved a USD 30 million milestone in its DARZALEX collaboration with Janssen Biotech, Inc.. The milestone payment was triggered by the first c
5/30/16 - Government to conduct study to assess impact of FDI in pharma industry [Qatar Tribune]
The Commerce and Industry Ministry has commissioned a study to assess the impact of foreign direct investment in pharmaceutical companies amid concerns over mergers and acquisitions of domestic drug manufacturers. "An expert from academic field has been engaged in this exercise along with the National Productivity Council," an official said.
5/30/16 - GOVT TO SUPPLY FREE HEPATITIS MEDICINES IN HOSPITALS [Pakistan Observer]
The price of the medicine, which is called Sofigates, is Rs 1,318 for a pack of 28 tablets for one month while six months course is enough for treatment of a patient of hepatitis. Earlier, this medicine had been selling in Rs 55,000 per pack of 28 tablets by some foreign drug companies but now after giving the approval to 11 local companies, this m
5/30/16 - Guatemalan Pharmaceutical Company Looking to Expand into Egypt [Palestine Chronicle, The]
During a visit to Egypt this week, Luna del Pinal handed over a proposal to the Egyptian authorities to establish a network of 2,000 pharmacies across the country. The businessman considers that Egypt, which has a population of 90 million, represents a large market for his Farmacias de la Comunidad, which means Community Pharmacies, as 25 percent o
5/30/16 - Guest column: Transparency in medicine isn't a one-way street
A majority of Americans believe increased healthcare transparency should be a top national priority. It's easy to understand why. Consider the "prescription price shell game" uncovered in Minneapolis, where a local CVS jacked up the price of a kidney medication to more than $6 per pill from 87 cents.
5/30/16 - Human Genome Sciences Stock May Benefit from Big Pharma Breakthroughs
Big pharmaceutical companies like Amgen, Sanofi and Regeneron Pharmaceuticals are achieving major breakthroughs backed by genetics research.. In a press release, Calico Chief Scientific Officer David Botstein stated, our common experience suggests that there may be hereditary factors underlying longevity, but finding the genes responsible using.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415